Advertisement

Sleep and Breathing

, Volume 12, Issue 2, pp 149–154 | Cite as

Circulating nitric oxide (NO), asymmetric dimethylarginine (ADMA), homocysteine, and oxidative status in obstructive sleep apnea–hypopnea syndrome (OSAHS)

  • Yeşim Ozkan
  • Hikmet Fırat
  • Bolkan Şimşek
  • Meral Torun
  • Sevgi Yardim-Akaydin
Original Article

Abstract

Obstructive sleep apnea–hypopnea syndrome (OSAHS) with episodic hypoxia–reoxygenation is associated with increased cardiovascular morbidity and mortality. Therefore, increased homocysteine, asymmetric dimethylarginine (ADMA), oxidative status, and decreased nitric oxide levels have been implicated as possible mechanisms for development of cardiovascular diseases. We aimed to investigate changes in the levels of these substances in patients with OSAHS in comparison with nonapneic controls. Thirty-four OSAHS patients and 15 healthy controls were included in this study. In the blood samples, oxidative status and nitric oxide levels were measured with spectrophotometric methods. Plasma ADMA and homocysteine levels were determined by using high-performance liquid chromatography with fluorescence detection. Nitric oxide levels were significantly low in OSAHS patients (p < 0.05) and correlated with mean SaO2 (r = 0.513, p < 0.002) and lowest SaO2 (r = 0.363, p < 0.03). Oxidative status, ADMA, and homocysteine levels were higher in OSAHS patients, but difference did not reach statistical significance. After dividing patients into moderate (AHI = 5–29) and severe (AHI ≥ 30) OSAHS groups, significantly increased homocysteine levels were observed in the severe OSAHS group (p < 0.05). Nitric oxide levels negatively correlated with oxidative status in total OSAHS patients (r = −0.415, p < 0.02) and also in severe OSAHS group (r = −0.641, p < 0.007). Hyperhomocysteinemia and diminished NO production may be causal factors in endothelial dysfunction seen in OSAHS and may explain the association between OSAHS and cardiovascular diseases. These modifiable factors should be monitored in patients suspected of having OSAHS.

Keywords

ADMA Apnea Homocysteine Nitric oxide Oxidative status Sleep apnea 

Notes

Acknowledgment

We thank Prof. Kemal Erbil and Asist. Prof. Erdinç Çakır for their helpful assistance in ADMA measurements. This study was supported by The Scientific and Technological Research Council of Turkey (SBAG-AYD-457, 104S066).

References

  1. 1.
    Baldwin CM, Bootzin RR, Schwenke DC, Quan SF (2005) Antioxidant nutrient intake and supplements as potential moderators of cognitive decline and cardiovascular disease in obstructive sleep apnea. Sleep Med Rev 9:459–476PubMedCrossRefGoogle Scholar
  2. 2.
    Jordan AS, McEvoy RD (2003) Gender differences in sleep apnea: epidemiology, clinical presentation and pathogenic mechanisms. Sleep Med Rev 7:377–389PubMedCrossRefGoogle Scholar
  3. 3.
    Barcelo A, Barbe F, de la Pena M, Vila M, Perez G, Pierola J, Duran J, Agusti AGN (2006) Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J 27:756–760PubMedCrossRefGoogle Scholar
  4. 4.
    Christou K, Markoulis N, Moulas AN, Pastaka C, Gourgoulianis KI (2003) Reactive oxygen metabolites (ROS) as an index of oxidative stress in obstructive sleep apnea patients. Sleep Breath 7:105–109PubMedCrossRefGoogle Scholar
  5. 5.
    Lavie L, Vishnevsky A, Lavie P (2004) Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 27:123–128PubMedGoogle Scholar
  6. 6.
    Gautier-Sauvigné S, Colas D, Parmantier P, Clement P, Gharib A, Sarda N, Cespuglio R (2005) Nitric oxide and sleep. Sleep Med Rev 9:101–113PubMedCrossRefGoogle Scholar
  7. 7.
    Lavie L (2003) Obstructive sleep apnoea syndrome—an oxidative stress disorder. Sleep Med Rev 7:35–51PubMedCrossRefGoogle Scholar
  8. 8.
    Moncada S, Palmer RMJ, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109–142PubMedGoogle Scholar
  9. 9.
    Haight JSJ, Djupesland PG (2003) Nitric oxide (NO) and obstructive sleep apnea (OSA). Sleep Breath 7:53–61PubMedCrossRefGoogle Scholar
  10. 10.
    Ip MSM, Lam B, Chan LY, Zheng L, Tsang KWT, Fung PCW, Fung PCW, Lam WK (2000) Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Repir Crit Care Med 162:2166–2171Google Scholar
  11. 11.
    Ohike Y, Kozaki K, Iijima K, Eto M, Kojima T, Ohga E, Santa T, Imai K, Hashimoto M, Yoshizumi M, Ouchi Y (2005) Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure—possible involvement of nitric oxide and asymmetric NG,NG-dimethylarginine. Cir J 69:221–226CrossRefGoogle Scholar
  12. 12.
    Schulz R, Schmidt D, Blum A, Lopes-Ribeiro X, Lucke C, Mayer K, Olschewski H, Seeger W, Grimminger F (2000) Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax 55:1046–1051PubMedCrossRefGoogle Scholar
  13. 13.
    Leiper JM, Vallance P (2006) The synthesis and metabolism of asymmetric dimethylarginine (ADMA). Eur J Clin Pharmacol 62:33–38CrossRefGoogle Scholar
  14. 14.
    Guldener CV, Stehouwer CDA (2000) Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost 26:281–289PubMedCrossRefGoogle Scholar
  15. 15.
    Weiss N (2005) Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab 6:27–36PubMedCrossRefGoogle Scholar
  16. 16.
    Bagi Z, Ungvari Z, Szollár L, Koller A (2001) Flow-induced constriction in arterioles of hyperhomocysteinemic rats is due to impaired nitric oxide and enhanced thromboxane A2 mediation. Arterioscler Thromb Vasc Biol 21:233–237PubMedGoogle Scholar
  17. 17.
    Dayal S, Lentz SR (2005) ADMA and hyperhomocysteinemia. Vasc Med 10:S27–33PubMedCrossRefGoogle Scholar
  18. 18.
    Stühlinger MC, Stanger O (2005) Asymetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction. Curr Drug Matab 6:3–14CrossRefGoogle Scholar
  19. 19.
    Rechtschaffen A, Kales A (1968) A Manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. NIH publication no. 204. National Institute of Neurological Disease and Blindness, Bethesda, MAGoogle Scholar
  20. 20.
    Miranda KM, Espey MG, Wink DA (2001) A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5:62–71PubMedCrossRefGoogle Scholar
  21. 21.
    Chen BM, Xia LW, Zhao RQ (1997) Determination of NG, NG-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B 692:467–471CrossRefGoogle Scholar
  22. 22.
    Verde V, Fogliano V, Ritieni A, Maiani G, Morisco F, Caporaso N (2002) Use of N,N-dimethyl-p-phenylenediamine to evaluate the oxidative status of human plasma. Free Radic Res 36:869–873PubMedCrossRefGoogle Scholar
  23. 23.
    Krıjt J, Vackova M, Kozıch V (2001) Measurement of homocysteine and other aminothiols in plasma: advantages of using tris(2-carboxyethyl)phosphine as reductant compared with tri-n-buthylphosphine. Clin Chem 47:1821–1828PubMedGoogle Scholar
  24. 24.
    Vester B, Rasmussen K (1991) High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 29:549–554PubMedGoogle Scholar
  25. 25.
    Lavie P, Herer P, Hoffstein V (2000) Obstructive sleep apnoea syndrome as a risk factor for hypertention: population study. BMJ 320:479–482PubMedCrossRefGoogle Scholar
  26. 26.
    Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto FJ, O'Connor GT, Boland LL, Schwartz JE, Samet JM (2001) Sleep-disordered breathing and cardiovascular disease: croos-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 163:19–25PubMedGoogle Scholar
  27. 27.
    Sin DD, Fitzgerald F, Parker JD, Newton G, Floras JS, Bradley TD (1999) Risk factors for central and obstructive apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 160:1101–1106PubMedGoogle Scholar
  28. 28.
    Von Kanel R, Le DT, Nelesen RA, Mills PJ, Ancoli-Israel S, Dimsdale JE (2001) The hypercoagulable state in sleep apnea is related to comorbid hypertention. J Hypertens 19:1445–1451CrossRefGoogle Scholar
  29. 29.
    Schulz R, Mahmoudi S, Hattar K, Sibelius U, Olschewski H, Mayer K, Seeger W, Grimminger F (2000) Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Am J Respir Crit Care Med 162:566–570PubMedGoogle Scholar
  30. 30.
    Çiftçi TU, Kokturk O, Bukan N, Bilgihan A (2004) The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine 28:87–91PubMedCrossRefGoogle Scholar
  31. 31.
    Carlson JT, Rangemark C, Hedner JA (1996) Attenuated endothelium-dependent vascular relaxation in patients with sleep apnoea. J Hypertens 14:577–584PubMedCrossRefGoogle Scholar
  32. 32.
    Hernández C, Abreu J, Abreu P, Colino R, Jimenéz A (2006) Effects of nasal positive airway pressure treatment on oxidative stress in patients with sleep apnea-hypopnea syndrome. Arch Bronconeumol 42:125–129PubMedCrossRefGoogle Scholar
  33. 33.
    Jordan W, Cohrs S, Degner D, Meier A, Rodenbeck A, Mayer G, Pilz J, Rüther E, Kornhuber J, Bleich S (2006) Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome. J Neural Transm 113:239–254PubMedCrossRefGoogle Scholar
  34. 34.
    Doshi S, McDowell I, Goodfellow J, Stabler S, Boger R, Allen R, Newcombe R, Lewis M (2005) Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia. Metabolism 54:351–360PubMedCrossRefGoogle Scholar
  35. 35.
    Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG (1999) Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 100:1161–1168PubMedGoogle Scholar
  36. 36.
    Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C (2005) Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 46:518–523PubMedCrossRefGoogle Scholar
  37. 37.
    Özkan Y, Özkan E, Şimşek B (2002) Plasma total homocysteine and cysteine levels as cardiovascular risk factors in coronary heart disease. Int J Cardiol 82:269–277PubMedCrossRefGoogle Scholar
  38. 38.
    Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R (2001) Risk of acute coronary events and serum concentration of asymmetric dimethylarginine. Lancet 358:2127–2128PubMedCrossRefGoogle Scholar
  39. 39.
    Lavie L, Perelman A, Lavie P (2001) Plasma homocysteine levels in obstructive sleep apnea. Association with cardiovascular morbidity. Chest 120:900–908PubMedCrossRefGoogle Scholar
  40. 40.
    Jordan W, Berger C, Cohrs S, Rodenbeck A, Mayer G, Niedmann PD, von Ahsen N, Rüther E, Kornhuber J, Bleich S (2004) CPAP-therapy effectively lowers serum homocysteine in obstrüctive sleep apnea syndrome. J Neural Transm 111:683–689PubMedCrossRefGoogle Scholar
  41. 41.
    Kokturk O, Ulukavak-Ciftci T, Mollarecep E, Ciftci B (2006) Serum homocysteine levels and cardiovascular morbidity in obstructive sleep apnea syndrome. Respir Med 100:536–541PubMedCrossRefGoogle Scholar
  42. 42.
    Cheng CH, Huang MC, Liu SC, Lin KL, Huang YC (2006) Traditional cardiovascular risk factors but not homocysteine are associated with obstructive sleep apnea. Nutr Res 26:59–64CrossRefGoogle Scholar
  43. 43.
    Robinson GV, Pepperell JCT, Segal HC, Davies RJO, Stradling JR (2004) Circulating cardiovascular risk factors in obstructive sleep apnea: data from randomized controlled trials. Thorax 59:777–782PubMedCrossRefGoogle Scholar
  44. 44.
    Yildirim AO, Bulau P, Zakrzewicz D, Kitowska KE, Weissmann N, Grimminger F, Morty RE, Eickelberg O (2006) Increased protein arginine methylation in chronic hypoxia: role of protein arginine methyltransferases. Am J Respir Cell Mol Biol 35:436–443PubMedCrossRefGoogle Scholar
  45. 45.
    Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC (2005) Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol 289:H2649–2656PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Yeşim Ozkan
    • 1
  • Hikmet Fırat
    • 2
  • Bolkan Şimşek
    • 1
  • Meral Torun
    • 1
  • Sevgi Yardim-Akaydin
    • 1
  1. 1.Department of Biochemistry, Faculty of PharmacyGazi UniversityEtilerTurkey
  2. 2.Sleep Disorders Center, Department of Chest DiseasesDışkapı Education and Research HospitalAnkaraTurkey

Personalised recommendations